Share Name Share Symbol Market Type Share ISIN Share Description
4d Pharma Plc LSE:DDDD London Ordinary Share GB00BJL5BR07 ORD 0.25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.90 -1.06% 84.20 83.70 84.60 86.30 83.50 86.20 592,225 16:35:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.5 -30.3 -22.8 - 152

4D pharma to Participate in 5th Microbiome Movement Drug Development Summit Europe

21/01/2021 12:00pm

Business Wire

4d Pharma (LSE:DDDD)
Historical Stock Chart

From Jul 2020 to Jul 2021

Click Here for more 4d Pharma Charts.

4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome, today announced its participation in the Microbiome Movement Drug Development Summit – Europe, including the Plenary Session, Microbiome Leaders Industry Review Panel.

  • Plenary Session: European Microbiome Leaders Panel Discussion on Thursday, January 28, 2021 at 8:00am GMT (3:00am ET) with Chief Scientific Officer, Dr. Alex Stevenson, Ph.D.
  • Clinical Trial Design and Evaluating PK/PD Session: MicroRx® and Single Strain Live Biotherapeutics: Proof of Concept Clinical Data and Future Considerations on Thursday, January 28, 2021 at 11:30pm GMT (6:30am ET) with Research Director, Dr. Imke Mulder

About 4D pharma

Founded in February 2014, 4D pharma is a world leader in the development of Live Biotherapeutics, a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacterium, that is applicable to the prevention, treatment or cure of a disease. 4D has developed a proprietary platform, MicroRx®, that rationally identifies Live Biotherapeutics based on a deep understanding of function and mechanism.

4D pharma's Live Biotherapeutic products (LBPs) are orally delivered single strains of bacteria that are naturally found in the healthy human gut. The Company has six clinical programs, namely a Phase I/II study of MRx0518 in combination with KEYTRUDA (pembrolizumab) in solid tumors, a Phase I study of MRx0518 in a neoadjuvant setting for patients with solid tumors, a Phase I study of MRx0518 in patients with pancreatic cancer, a Phase I/II study of MRx-4DP0004 in asthma, a Phase II study of MRx-4DP0004 in patients hospitalized with COVID-19, and Blautix® in Irritable Bowel Syndrome (IBS) which has completed a successful Phase II trial. Preclinical-stage programs include candidates for CNS disease such as Parkinson's disease and other neurodegenerative conditions. The Company has a research collaboration with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ, USA, to discover and develop Live Biotherapeutics for vaccines.

For more information, refer to

4D pharma Duncan Peyton, Chief Executive Officer +44 (0)113 895 0130 Investor Relations:

N+1 Singer - Nominated Adviser and Joint Broker +44 (0)20 7496 3000 Philip Davies / Justin McKeegan / Iqra Amin (Corporate Finance) Tom Salvesen (Corporate Broking)

Bryan Garnier & Co. Limited - Joint Broker +44 (0)20 7332 2500 Dominic Wilson / Phil Walker

Stern Investor Relations, Inc. +1-212-362-1200 Julie Seidel

Image Box Communications +44 (0)20 8943 4685 Neil Hunter / Michelle Boxall

1 Year 4d Pharma Chart

1 Year 4d Pharma Chart

1 Month 4d Pharma Chart

1 Month 4d Pharma Chart
ADVFN Advertorial
Your Recent History
4d Pharma
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20210725 18:45:16